Suvecaltamide
As of the edition of 20 October 2026, Suvecaltamide is a small molecule: stopped in 2020; acts on CACNA1G, CACNA1H and CACNA1I.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2020
- Kind
- Small molecule
- Registered trials
- 6, 1 stopped early
- Disease areas
- Nervous system; Mental health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 6 | 5 | 0 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Merck & Co. | Lead sponsor of trials | 2009 to now |
| Jazz Pharmaceuticals | Lead sponsor of trials | 2017 to now |